Search Results - antibodies

59 Results

Sort By:

bio-IB3

Unmet NeedAccording to the CDC, approximately 5.8-million individuals aged 65+ in the United States were living with Alzheimer’s disease in 2020 (see CDC). Alzheimer’s disease leads to memory impairment that progressively affects the ability of individuals to conduct daily tasks and worsens with time. Currently, the diagnosis of Alzheimer’s disease...

Published: 3/12/2026 | Inventor(s): Esther Oh, Stina Tucker, David Borchelt, Juan Troncoso

Keywords(s): Alzheimer's Disease, Antibodies, Biologics, CNS and Neurological Disorders, Discovery/Research Tools, Disease Indication, Neurodegeneration, Research Reagent, Therapeutic Matter, Therapeutic Substance, Therapeutics, Translational Research Biomarker

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Geriatrics, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Research Tools > Antibodies, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Neurology, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Neurodegeneration

Targeting of Myeloid-Derived Suppressor Cells (MDSCs) for Cancer Treatment

Value Proposition· Addresses key resistance mechanism: targets MDSCs, a central driver of resistance to immune checkpoint inhibitors in metastatic and poorly immunogenic cancers· Synergistic combination strategy: Combines epigenetic modulators (HDAC and DNA methyltransferase inhibitors) with anti-PD-1 and anti-CTLA-4 antibodies to restore...

Published: 3/12/2026 | Inventor(s): KiBem Kim, Bert Vogelstein, Kenneth Kinzler, Shibin Zhou

Keywords(s): Antagonists/Inhibitors, Antibodies, Biologics, Cancers, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Novel monoclonal antibody inhibitors targeting potassium channel KCNK9

Unmet Need:KCNK9 is one of 15 mammalian subtypes in the highly conserved family of two-pore domain potassium channels (K2P). Under physiological conditions, KCNK9 is primarily expressed in the brain where it serves to maintain cellular membrane potentials. However, overexpression of KCNK9 has been detected in breast, lung, skin, and other cancers, and...

Published: 3/12/2026 | Inventor(s): John Laterra, Han Sun, Min Li, Amy Fulton

Keywords(s): Antibodies, Biologics, Breast Cancer, Cancers, Disease Indication, Lung Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Respiratory Diseases, Clinical and Disease Specializations > Women's Health, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Breast Cancer, Clinical and Disease Specializations > Oncology > Lung Cancer

A Novel and Unique Set of Human Antibodies to Human Resistin and to Human Resitin-like Molecule Beta (RELMB) that can be used to Target these Proteins in Human Disease

Unmet NeedAutoinflammatory responses, your body’s innate defense mechanism against infections and stressors, can become overactive and cause chronic inflammation in various tissues and organs. Inflammatory diseases affect more than 200 million people worldwide and include pulmonary hypertension, scleroderma, rheumatoid arthritis, pulmonary fibrosis,...

Published: 3/12/2026 | Inventor(s): Roger Johns

Keywords(s): Antibodies, Biologics, Cardiovascular Diseases, Disease Indication, Hypertension, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Cardiovascular > Hypertension

Hybridoma expressing anti-RG-1 mAb for the study of human papillomavirus L2

Technology DescriptionJHU scientists generated a hybridoma expressing a monoclonal antibody, RG-1, that binds to highly conserved L2 residues and neutralizes human papillomavirus 16 (HPV16) and HPV18. Passive immunotherapy with RG-1 was protective in mice. Antiserum to the HPV16 L2 peptide comprising conserved residues neutralized pseudoviruses HPV5,...

Published: 3/12/2026 | Inventor(s): Ratish Gambhira, Richard Roden

Keywords(s): Antibodies, Basic Research Biomarker, Cell Model, Discovery/Research Tools, Hybridomas, In Vitro Research Tool, Monoclonal Antibodies, Research Reagent

Category(s): Technology Classifications > Research Tools > Antibodies, Technology Classifications > Research Tools > Cell Lines, Technology Classifications > Research Tools

Highly Specific Monoclonal Antibodies used as Allosteric Inhibitors and Specific Biosensors of Human ZnT8

Unmet NeedType 2 diabetes (T2D) is a growing worldwide public health issue affecting over 500 million people while creating a $1 trillion economic burden on global healthcare economies. Many current and new therapeutics demonstrate varying degrees of effectiveness, but no single agent or combination thereof has been able to provide patients with lasting...

Published: 3/13/2026 | Inventor(s): Dax Fu, Chengfeng Merriman

Keywords(s): Antibodies, Biologics, Diabetes, Discovery/Research Tools, Disease Indication, Metabolic Disorders, Monoclonal Antibodies, Research Reagent, Therapeutic Matter, Therapeutic Substance, Therapeutics, Translational Research Biomarker, Type II Diabetes

Category(s): Technology Classifications > Research Tools > Research Antibodies, Clinical and Disease Specializations > Diabetes > Type 2 Diabetes, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

Rapid Assay for Carcinoma Stem Cells

Unmet NeedWhile cancer therapeutics have drastically improved patient outcomes in numerous indications, novel methods to prevent cancer metastasis and recurrence are needed. Cancer stem cells (CSCs) are a unique subpopulation of a tumor that are more oncogenic and slow-growing than other cancer cells within the tumor. CSCs make up approximately .1-10%...

Published: 3/12/2026 | Inventor(s): William Matsui, Xiaobing He, David Berman

Keywords(s): Antibodies, Biologics, Bladder Cancer, Cancers, Disease Indication, Immunotherapy, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Urology, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Oncology > Bladder Cancer

Neuritin Impact T Cell Tolerance Induction and Maintenance and is a Target for Tumor Immunotherapy

Unmet NeedCancer immunotherapy is a therapeutic approach that has revolutionized advanced cancer treatment. In particular, the use of therapeutic blocking antibodies to cytotoxic T-lymphocyte antigen 4 (CTLA4) and programmed cell death protein (PD-1) has achieved routine clinical use in numerous indications. Despite these promising results, monotherapy...

Published: 3/13/2026 | Inventor(s): Drew Pardoll, Hong Yu, Joseph Barbi, Fan Pan, Charles Drake

Keywords(s): Antibodies, Autoimmune Diseases, Biologics, Cancers, Combination, Disease Indication, Inflammatory Disorders, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Autoimmunity, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

Screening Method to Identify Scleroderma Immune Responses with Anti-cancer Activity, and Induction of such Immune Responses for Cancer Therapy

Unmet NeedEpidemiological studies have shown that patients with scleroderma, a type of autoimmune rheumatic disease affecting the skin and connective tissues, have an increased risk of developing cancer relative to the general population. The exact etiology of scleroderma is still unknown. The Scleroderma Foundation estimates about 100,000 to 300,000...

Published: 3/13/2026 | Inventor(s): Ami Shah, Livia Casciola-Rosen, Antony Rosen, Takeru Igusa, Marikki Laiho

Keywords(s): Antibodies, Autoimmune Diseases, Biologics, Biomarker, Cancers, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Inflammatory Disorders, Risk Stratification, Scleroderma, Skin Disorders, Skin Fibrosis, Therapeutic Matter, Therapeutic Substance, Therapeutics

Antibodies to Visual Pigment Proteins, Transcription Factor Sox17, and Multimerized Epitope Tags

Unmet Need:Canonical Wnt signaling is one of the major pathways involved in embryonic development and tissue regeneration. Recent studies suggest that canonical Wnt signaling is vital for brain angiogenesis and the acquisition of barrier properties by the microvasculature. There is a need in the field for the development of reagents that allow for the...

Published: 3/13/2026 | Inventor(s): Jeremy Nathans

Keywords(s): Antibodies, Discovery/Research Tools, Labels/Markers, Monoclonal Antibodies, Research Reagent

Category(s): Technology Classifications > Research Tools > Proteins, Ligands & Receptors, Technology Classifications > Research Tools > Research Antibodies

1 2 3 4 5 6